# US 2019/0169171 A1 · Fluorine- and/or deuterium-containing compounds for treating non-small cell lung cancer and related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169171 A1
- Document ID: US20190169171A1
- Status: Published application
- Kind: A1
- Application number: 16/149,172
- Filed: 2018-10-02
- Published: 2019-06-06
- Earliest claimed: 2017-10-03
- Assignees: X-Cutag Therapeutics, Inc.
- Applicants: X-Cutag Therapeutics, Inc.
- Inventors: Changfu CHENG; Shuhao WEN; Hui Joyce LI
- Web page: https://patentgrep.com/patent/US20190169171A1

## CPC

- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61P 35/00: Antineoplastic agents
- C07B 59/002: {Heterocyclic compounds}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Novel fluoride and/or deuterium-containing chemical, compounds useful for treating cancer or a related disease or disorder thereof, and pharmaceutical compositions and methods of preparation and use thereof.

## Claims

### Claim 1

A compound of the following Formula (I) or a pharmaceutically acceptable salt or ester thereof:
wherein each of R1, R2, R3, R4, R5 and R6 is independently selected from the group consisting of H, F and D, and at least one of R1, R2, R3, R4, R5 or R6 is F.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each of R1 in the compound is F and each of R2, R3, R4, R5 and R6 is H, having the structural Formula (II):

### Claim 3 (depends on 1)

The compound of claim 1, wherein each of R2 and R3 in the compound is F and each of R1, R4. R5 and R6 is H, having the structural Formula (III):

### Claim 4 (depends on 1)

The compound of claim 1, wherein each of R1, R2 and R3 in the compound is F, and each of R4, R5 and R6 is H, having the structural formula (IV):

### Claim 5 (depends on 1)

The compound of claim 1, wherein each of R1, R2 and R3 in the compound is H, and each of R4, R5 and R6 is F, having the structural formula (V):

### Claim 6 (depends on 1)

The compound of claim 1, wherein each of R1 in the compound is F, each of R2 and R3 is H, and each of R4, R5 and R6 is F, having the structural formula (VI):

### Claim 7 (depends on 1)

The compound of claim 1, wherein each of R2 and R3 in the compound is F, R1 is H, and each of R4, R5 and R6 is F, having the structural formula (VII):

### Claim 8 (depends on 1)

The compound of claim 1, wherein each of R1, R2, R3, R4, R5 and R6 in the compound is F, having the structural formula (VIII):

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 is F, each of R2 and R3 is H, and each of R4, R5 and R6 in the compound is D, having the structural formula (IX):

### Claim 10 (depends on 1)

The compound of claim 1, wherein R1 is H, each of R2 and R3 is F, and each of R4, R5 and R6 in the compound is D, having the structural formula (X):

### Claim 11 (depends on 1)

The compound of claim 1, wherein each of R1, R2 and R3 is F, and each of R4, R5 and R6 in the compound is D, having the structural formula (XI):

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is in the form of a mesylate salt.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or ester thereof, effective to treat cancer or a related disease or disorder thereof in a mammal or a human, and a pharmaceutically acceptable excipient, earlier, or diluent.

### Claim 14 (depends on 1)

A unit dosage form comprising the pharmaceutical composition of claim 1.